MeSH D018234 - alveolar soft part sarcoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Genentech | Atezolizumab | Tecentriq | 2016-05-18 | |||
| Roche | Atezolizumab | Tecentriq | 2017-09-20 | $4,406.336 M | Q4/22-Q3/23 |
Clinical Trials
Historical Success Rate
Phase 1
50%2/4
Phase 2
13%3/24
Phase 3
0%0/5
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use